Tag Archives: Andrew D’silva

B.Riley FBR Sticks to Its Buy Rating for Cumberland Pharmaceuticals (CPIX)

In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cumberland Pharmaceuticals (CPIX – Research Report), with a price target of $9.75. The company’s shares closed last Monday at $5.24. According to TipRanks.com, D’silva is

B.Riley FBR Maintains Their Buy Rating on Cumberland Pharmaceuticals (CPIX)

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Cumberland Pharmaceuticals (CPIX – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $4.75, close to its 52-week low of $4.70. According

Alimera (ALIM) Received its Third Buy in a Row

After H.C. Wainwright and Craig-Hallum gave Alimera (NASDAQ: ALIM) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Andrew D’silva maintained a Buy rating on Alimera yesterday and set a price target of

Harrow Health (HROW) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Harrow Health (HROW – Research Report) today and set a price target of $12.75. The company’s shares closed last Monday at $4.60, close to its 52-week low of $4.10. According

EyePoint Pharmaceuticals (EYPT) Receives a Buy from B.Riley FBR

In a report issued on November 8, Andrew D’silva from B.Riley FBR maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $1.45, close to its

Intricon (IIN) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Intricon (IIN – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $21.44. According to TipRanks.com, D’silva is a 1-star analyst with